Zamarrón *et al*. \[[@CIT0001]\] report that obstructive sleep apnoea syndrome (OSAS) is associated with raised levels of markers of endothelial function. Moreover, some of these markers (intercellular cell adhesion molecule-1 (ICAM-1) and plasminogen activator inhibitor-1 (PAI-1)) improved after nasal continuous positive airway pressure \[[@CIT0001]\]. Some additional comments may be of interest.

Metabolic syndrome (MetS) is highly prevalent in patients with OSAS \[[@CIT0002]\]. In turn, intermittent hypoxia increases insulin resistance \[[@CIT0002]\]. Consequently, it is difficult to identify the contribution of OSAS and MetS to vascular risk, since they share common predisposing factors (e.g. obesity \[[@CIT0002]\] and endothelial dysfunction \[[@CIT0003]\]). Markers of endothelial activation, including ICAM-1, PAI-1 and E-selectin, are raised in MetS \[[@CIT0003]\] and Zamarrón *et al*. \[[@CIT0001]\] report a similar pattern in OSAS. Platelet activation occurs in MetS due to reduced availability of endothelium-derived nitric oxide (NO) and prostacyclin \[[@CIT0004]\]. Similarly, in OSAS a decrease in NO availability and prostacyclin/thromboxane metabolite ratio has been reported \[[@CIT0002], [@CIT0005]\]. Markers of platelet activation, including mean platelet volume (MPV) and platelet distribution width (PDW), were increased in OSAS, in parallel with the severity of hypoxia \[[@CIT0006]\]. Therefore, it would be helpful to know how many patients in the control and OSAS group had MetS in the Zamarrón *et al*. \[[@CIT0001]\] study.

Taken together, all these findings highlight the role of OSAS on endothelial integrity and as a contributor to cardiovascular risk.
